Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Novo specifically requested semaglutide be added to the FDA’s Demonstrable Difficulties for Compounding lists, citing complexities around formulations, delivery mechanisms, dosage forms ...

Tirzepatide and semaglutide both belong to a class of drugs known as GLP-1s. Compounding pharmacies have been producing copycat versions of the drugs while they have been in short supply.

This is thanks to exponential growth from compounding. You don’t have to be a Nobel Prize winner like Einstein to benefit from the power of compounding. Here’s how to open a compound interest ...

"FDA continues to monitor supply and demand for these products." Since the shortage began, specialty and compounding pharmacies have been allowed to sell off-brand versions of the weight loss drug.